Related Experiment Video
Updated: Dec 13, 2025
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
8.3K
GlyT1 encephalopathy: Characterization of presumably disease causing GlyT1 mutations
1Department of Anaesthesiology and Intensive Care, University of Leipzig, Leipzig, Germany.
Neurochemistry International
|July 27, 2020
Summary
Mutations in the Glycine Transporter 1 (GlyT1) gene cause GlyT1 encephalopathy, a severe neurological disorder. This study functionally characterizes these mutations, revealing they severely impair transporter function, consistent with disease causation.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Glycine is a key inhibitory neurotransmitter in the central nervous system (CNS).
- Extracellular glycine levels are regulated by Glycine Transporter 1 (GlyT1) and Glycine Transporter 2 (GlyT2).
- Mutations in SLC6A9 (encoding GlyT1) are linked to GlyT1 encephalopathy, characterized by respiratory and muscular issues.
Purpose of the Study:
- To functionally characterize GlyT1 mutations associated with GlyT1 encephalopathy.
- To investigate the impact of specific GlyT1 mutations on transporter activity and cellular localization.
Main Methods:
- Functional characterization of four GlyT1 mutations (GlyT1Q573*, GlyT1K310F+fs*31, GlyT1S407G, GlyT1V118M) in recombinant systems.
- Analysis of protein processing, cellular localization, and glycine transport activity.
Main Results:
- Two truncating mutations (GlyT1Q573* and GlyT1K310F+fs*31) resulted in intracellular retention and complete loss of transport activity.
- Two missense mutations (GlyT1S407G and GlyT1V118M) were correctly processed but exhibited severely diminished transport activity.
- All analyzed GlyT1 mutations lead to a significant impairment of transporter function.
Conclusions:
- Loss of GlyT1 function due to mutations is directly causal for the GlyT1 encephalopathy phenotype.
- The study provides crucial functional insights into the molecular mechanisms underlying GlyT1 encephalopathy.
More Related Videos
Related Concept Videos
01:22Lysosomal Hydrolases
4.3K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
01:20Inborn Errors of Metabolism
615
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
615
01:27Glucose Transporters
26.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.9K
03:03Amyloid Fibrils
11.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.4K